# Appendix Tables

Appendix Table 1: Matching variables for each comparison

|  |  |
| --- | --- |
|  | Matching variables |
| CRT vs. RT – 2000-2005 | * age
* race
* sex
* marital status
* tract median income
* CCI score
* stage
* region (South vs. other regions)
 |
| CRT vs. RT – 2006-2011 | * age
* race
* marital status
* tract median income
* CCI score
* stage
* region (South vs. other regions)
 |
| Cetux vs. RT – 2006-2011 | * age
* race
* marital status
* tract median income
* CCI score
* stage
* region (South vs. other regions)
 |
| Cetux vs. CRT – 2006-2011 | * age
* race
* marital status
* tract Median income
* CCI score
* stage

region (South, Midwest, other regions) |

\*CCI: Charlson Comorbidity Index

Appendix Table 2: Censoring rates at 5 years, stratified by treatment groups and diagnosis period

|  |  |
| --- | --- |
| Group | Censoring N (%) at 5 years |
| Full sample (N=2,055) | 349 (17) |
|  2000-2005 (N=922) | 0 |
|  RT (N=531) | 0 |
|  CRT (N=391) | 0 |
|  2006-2011 (N=1133) | 349 (31) |
|  RT (N=527) | 159 (30) |
|  CRT (N=349) | 126 (36) |
|  Cetuximab-RT (N=257) | 64 (25) |

Appendix Table 3: Characteristics of the matched sample comparing the RT and CRT groups in Cohort I

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | Treatment group |  |
| Overall(N=530) | RT(N=265) | CRT(N=265) | Standardized mean difference |
| N | % | N | % | N | % |  |
| Age | 153 | (28.9) | 75 | (28.3) | 78 | (29.4) | 0.09 |
|  66-69 |  |
|  70-74 | 168 | (31.7) | 88 | (33.2) | 80 | (30.2) |  |
|  75-79 | 129 | (24.3) | 60 | (22.6) | 69 | (26.0) |  |
|  80+ | 80 | (15.1) | 42 | (15.8) | 38 | (14.3) |  |
| Sex | 358 | (67.5) | 178 | (67.2) | 180 | (67.9) | 0.02 |
|  Male |  |
|  Female | 172 | (32.5) | 87 | (32.8) | 85 | (32.1) |  |
| Race | 465 | (87.7) | 235 | (88.7) | 230 | (86.8) | 0.12 |
|  White |  |
|  African-American | 48 | (9.1) | \* | \* | \* | \* |  |
|  Other | 17 | (3.2) | \* | \* | \* | \* |  |
| Married | 265 | (50.0) | 132 | (49.8) | 133 | (50.2) | -0.01 |
|  No |  |
|  Yes | 265 | (50.0) | 133 | (50.2) | 132 | (49.8) |  |
| Urban residence | \* | \* | \* | \* | \* | \* | 0.00 |
|  No |  |
|  Yes | \* | \* | \* | \* | \* | \* |  |
| CCI score | 300 | (56.6) | 152 | (57.4) | 148 | (55.8) | 0.02 |
|  0 |  |
|  1 | 129 | (24.3) | 64 | (24.2) | 65 | (24.5) |  |
|  2+ | 101 | (19.1) | 49 | (18.5) | 52 | (19.6) |  |
| Stage | 83 | (15.7) | 41 | (15.5) | 42 | (15.8) | 0.01 |
|  Localized |  |
|  Regional | 447 | (84.3) | 224 | (84.5) | 223 | (84.2) |  |
| Census tract median income quartile | 117 | (22.1) | 57 | (21.5) | 60 | (22.6) | 0.08 |
|  1st  |  |
|  2nd  | 137 | (25.8) | 71 | (26.8) | 66 | (24.9) |  |
|  3rd  | 131 | (24.7) | 68 | (25.7) | 63 | (23.8) |  |
|  4th  | 145 | (27.4) | 69 | (26.0) | 76 | (28.7) |  |
| Region\*\* | 155 | (29.2) | 78 | (29.4) | 77 | (29.1) | -0.01 |
|  South |  |
|  Other regions | 375 | (70.8) | 187 | (70.6) | 188 | (70.9) |  |

\* Per data use agreement, cell sizes less than 11 cannot be shown or derived

\*\* Patients were matched on South vs other regions given that South was the only region with different cost and survival outcomes

Appendix Table 4: Characteristics of the matched sample comparing the RT and CRT groups in Cohort II

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | Treatment group | Standardized mean difference |
| Overall(N=546) | RT(N=273) | CRT(N=273) |
| N | % | N | % | N | % |
| Age | 209 | (38.3) | 101 | (37.0) | 108 | (39.6) | 0.09 |
|  66-69 |  |
|  70-74 | 196 | (35.9) | 101 | (37.0) | 95 | (34.8) |  |
|  75-79 | 86 | (15.8) | 42 | (15.4) | 44 | (16.1) |  |
|  80+ | 55 | (10.1) | 29 | (10.6) | 26 | (9.5) |  |
| Sex | 424 | (77.7) | 212 | (77.7) | 212 | (77.7) | 0.05 |
|  Male |  |
|  Female | 122 | (22.3) | 61 | (22.3) | 61 | (22.3) |  |
| Race | 502 | (91.9) | 252 | (92.3) | 250 | (91.6) | 0.00 |
|  White |  |
|  African-American | \* | \* | \* | \* | \* | \* |  |
|  Other | \* | \* | \* | \* | \* | \* |  |
| Married | 231 | (42.3) | 120 | (44.0) | 111 | (40.7) | 0.07 |
|  No |  |
|  Yes | 315 | (57.7) | 153 | (56.0) | 162 | (59.3) |  |
| Urban residence | \* | \* | \* | \* | \* | \* | -0.02 |
|  No |  |
|  Yes | \* | \* | \* | \* | \* | \* |  |
| CCI score | 294 | (53.8) | 147 | (53.8) | 147 | (53.8) | 0.09 |
|  0 |  |
|  1 | 145 | (26.6) | 76 | (27.8) | 69 | (25.3) |  |
|  2+ | 107 | (19.6) | 50 | (18.3) | 57 | (20.9) |  |
| Stage | 70 | (12.8) | 33 | (12.1) | 37 | (13.6) | 0.04 |
|  Localized |  |
|  Regional | 476 | (87.2) | 240 | (87.9) | 236 | (86.4) |  |
| Census tract median income quartile | 142 | (26.0) | 71 | (26.0) | 71 | (26.0) | 0.06 |
|  1st  |  |
|  2nd  | 143 | (26.2) | 74 | (27.1) | 69 | (25.3) |  |
|  3rd  | 121 | (22.2) | 57 | (20.9) | 64 | (23.4) |  |
|  4th  | 140 | (25.6) | 71 | (26.0) | 69 | (25.3) |  |
| Region\*\* | 178 | (32.6) | 83 | (30.4) | 95 | (34.8) | 0.09 |
|  South |  |
|  Other regions | 368 | (67.4) | 190 | (69.6) | 178 | (65.2) |  |

\* Per data use agreement, cell sizes less than 11 cannot be shown or derived

\*\* Patients were matched on South vs other regions given that South was the only region with different cost outcomes

Appendix Table 5: Characteristics of the matched sample comparing the RT and cetuximab-RT groups in Cohort II

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | Treatment group | Standardized mean difference |
| Overall(N=448) | RT(N=224) | Cetuximab-RT(N=224) |
| N | % | N | % | N | % |
| Age | 124 | (27.7) | 64 | (28.6) | 60 | (26.8) | 0.08 |
|  66-69 |  |
|  70-74 | 150 | (33.5) | 72 | (32.1) | 78 | (34.8) |  |
|  75-79 | 78 | (17.4) | 37 | (16.5) | 41 | (18.3) |  |
|  80+ | 96 | (21.4) | 51 | (22.8) | 45 | (20.1) |  |
| Sex | 346 | (77.2) | 166 | (74.1) | 180 | (80.4) | -0.04 |
|  Male |  |
|  Female | 102 | (22.8) | 58 | (25.9) | 44 | (19.6) |  |
| Race | 420 | (93.8) | 213 | (95.1) | 207 | (92.4) | 0.13 |
|  White |  |
|  African-American | \* | \* | \* | \* | \* | \* |  |
|  Other | \* | \* | \* | \* | \* | \* |  |
| Married | 177 | (39.5) | 92 | (41.1) | 85 | (37.9) | 0.06 |
|  No |  |
|  Yes | 271 | (60.5) | 132 | (58.9) | 139 | (62.1) |  |
| Urban residence | \* | \* | \* | \* | \* | \* | 0.20 |
|  No |  |
|  Yes | \* | \* | \* | \* | \* | \* |  |
| CCI score | 244 | (54.5) | 122 | (54.5) | 122 | (54.5) | 0.06 |
|  0 |  |
|  1 | 103 | (23.0) | 53 | (23.7) | 50 | (22.3) |  |
|  2+ | 101 | (22.5) | 49 | (21.9) | 52 | (23.2) |  |
| Stage | 51 | (11.4) | 23 | (10.3) | 28 | (12.5) | 0.07 |
|  Localized |  |
|  Regional | 397 | (88.6) | 201 | (89.7) | 196 | (87.5) |  |
| Census tract median income quartile | 73 | (16.3) | 36 | (16.1) | 37 | (16.5) | 0.07 |
|  1st  |  |
|  2nd  | 123 | (27.5) | 64 | (28.6) | 59 | (26.3) |  |
|  3rd  | 127 | (28.3) | 61 | (27.2) | 66 | (29.5) |  |
|  4th  | 125 | (27.9) | 63 | (28.1) | 62 | (27.7) |  |
| Region\*\* | 105 | (23.4) | 53 | (23.7) | 52 | (23.2) | -0.01 |
|  South |  |
|  Other regions | 343 | (76.6) | 171 | (76.3) | 172 | (76.8) |  |

\* Per data use agreement, cell sizes less than 11 cannot be shown or derived

\*\* Patients were matched on South vs other regions given that South was the only region with different cost outcomes

Appendix Table 6: Characteristics of the matched sample comparing the CRT and cetuximab-RT groups in Cohort II

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | Treatment group | Standardized mean difference |
| Overall(N=396) | CRT(N=198) | Cetuximab-RT(N=198) |
| N | % | N | % | N | % |
| Age | 121 | (30.6) | 61 | (30.8) | 60 | (30.3) | 0.03 |
|  66-69 |  |
|  70-74 | 140 | (35.4) | 70 | (35.4) | 70 | (35.4) |  |
|  75-79 | 88 | (22.2) | 44 | (22.2) | 44 | (22.2) |  |
|  80+ | 47 | (11.9) | 23 | (11.6) | 24 | (12.1) |  |
| Sex | 313 | (79.0) | 152 | (76.8) | 161 | (81.3) | 0.01 |
|  Male |  |
|  Female | 83 | (21.0) | 46 | (23.2) | 37 | (18.7) |  |
| Race | 366 | (92.4) | 184 | (92.9) | 182 | (91.9) | 0.05 |
|  White |  |
|  African-American | \* | \* | \* | \* | \* | \* |  |
|  Other | \* | \* | \* | \* | \* | \* |  |
| Married | 144 | (36.4) | 74 | (37.4) | 70 | (35.4) | -0.04 |
|  No |  |
|  Yes | 252 | (63.6) | 124 | (62.6) | 128 | (64.6) |  |
| Urban residence | \* | \* | \* | \* | \* | \* | 0.00 |
|  No |  |
|  Yes | \* | \* | \* | \* | \* | \* |  |
| CCI score | 222 | (56.1) | 109 | (55.1) | 113 | (57.1) | 0.13 |
|  0 |  |
|  1 | 93 | (23.5) | 51 | (25.8) | 42 | (21.2) |  |
|  2+ | 81 | (20.5) | 38 | (19.2) | 43 | (21.7) |  |
| Stage | 47 | (11.9) | 23 | (11.6) | 24 | (12.1) | -0.02 |
|  Localized |  |
|  Regional | 349 | (88.1) | 175 | (88.4) | 174 | (87.9) |  |
| Census tract median income quartile | 66 | (16.7) | 31 | (15.7) | 35 | (17.7) | 0.08 |
|  1st  |  |
|  2nd  | 90 | (22.7) | 44 | (22.2) | 46 | (23.2) |  |
|  3rd  | 123 | (31.1) | 62 | (31.3) | 61 | (30.8) |  |
|  4th  | 117 | (29.5) | 61 | (30.8) | 56 | (28.3) |  |
| Region\*\* | 26 | (6.6) | 13 | (6.6) | 13 | (6.6) | 0.05 |
|  Midwest |  |
|  South | 100 | (25.3) | 48 | (24.2) | 52 | (26.3) |  |
|  Other regions | 270 | (68.2) | 137 | (69.2) | 133 | (67.2) |  |

\* Per data use agreement, cell sizes less than 11 cannot be shown or derived

\*\* Patients were matched on Midwest vs South vs other regions given that the Midwest and South regions showed different cost outcomes compared to the other regions